French leaders differ on therapeutic cloning

13 February 2001

Opening the BioVision forum in Lyon, which was held last week, FrenchPresident Jacques Chirac said the technique of therapeutic cloning had led to the creation of embryos and cells for research purposes and, despite the ban, made reproductive cloning materially possible, with the risks of "commercial traffic in ovocytes."

His concern is shared to some degree by Germany's Chancellor, Gerhard Schroeder, who had said a few days earlier that he had doubts over therapeutic cloning and called for an ethical debate in Germany.

However, French Prime Minister Lionel Jospin's government is about to make such cloning possible. Draft revised legislation published at end-November 2000 would legalize it in "cases of necessity" and so ease the ban on embryo research in authorizing the retention of "surplus" embryos (created through in vitro fertilization) for a period of five years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight